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ABSTRACT
Shreya Roy, M.S.
University of Nebraska, 2015
Advisor: Anna Dunaevsky, PhD.

Maternal infection during pregnancy, which leads to maternal immune activation (MIA),
is an environmental risk factor for autism spectrum disorders (ASD). MIA can be induced
in mice and their offspring exhibit behaviors that model the core symptoms of ASD. One
of the core behavioral symptoms in ASD patients is presence of increased repetitive
behavior, which is modeled by an increase in marble burying in MIA mice. It has been
shown that the deficits seen in MIA mice are associated with the dysregulation of
cytokine levels in the developing brain, specifically an increase in pro-inflammatory
cytokines. In this thesis, I tested whether a reversal of this inflammatory state in the
brains of MIA mice by administration of an anti-inflammatory drug, Ibudilast, can
ameliorate the behavioral deficit. The results indicated that MIA mice exhibit increased
marble burying which is normalized by prenatal administration of Ibudilast without
significant effects on control mice. I also tried to establish an additional paradigm of
repetitive behavior in the MIA mice, using the rotarod and found that MIA mice have a
trend towards increased stereotyped motor routine as measured by an accelerating rotarod
test.
Altered behaviors in MIA mice are thought to be mediated by impaired synaptic
connectivity. Our lab recently showed structural and functional alterations in synapses in
the MIA offspring. An important component of the synapse are astrocytes, a type of glial
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cell, that regulate synapse formation and function. Whether astrocytic development and
function are impaired in MIA offspring is not known. Because cytokines have been
shown to modulate the release of transmitters from astrocytes it is possible that increase
in inflammatory state in MIA offspring can affect the signaling in astrocytes. Based on
these observations, I hypothesized that astrocytic calcium activity is altered in the brains
of MIA offspring and proposed to study the same using in-vivo astrocytic calcium
imaging.
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Chapter 1- INTRODUCTION

1.1 Maternal infection during pregnancy: risk factor for ASD- epidemiologic
evidence
Neural development is a highly orchestrated process, and any disturbance in the early
development of the CNS has been linked to neurological disorders, later in life1. There is
a dynamic interplay between genetic, epigenetic and environmental factors, which
influences early neural development. One such environmental factor which has been
implicated as a risk factor for autism spectrum disorders (ASD) is maternal infection2.
Epidemiologic studies have shown an association of maternal viral or bacterial infection
in the first and second trimester of pregnancy, respectively, to a diagnosis of ASD in the
offspring2. An early environmental insult like this induces a response of the maternal
immune system and is capable of affecting sensitive aspects of fetal brain development.
Here, I review the existing literature about how prenatal maternal immune activation
(MIA) can be a risk factor for ASD, what effects does MIA have on the synapse and what
are the known molecular mechanisms mediating these effects.
1.2 Immune dysfunction in ASD
Studies have demonstrated the presence of a neuroinflammatory state in autism patients.
One of the initial studies in this field investigated post-mortem brain tissue of ASD
patients; and revealed activation of neuroglia, a high prevalence of neuroglia-derived
cytokines, and an increase in pro-inflammatory cytokines in the cerebrospinal fluid of
autism patients3. This study was among the first to demonstrate immune dysfunction in
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the pathogenesis of ASD. Later studies provided pathological evidence to show activated
microglia and increased microglial density in the dorsolateral prefrontal cortex in autism4.
Such activated microglia had enlarged soma, retracted and thicker processes and
extending filopodia from the processes, which might play a role in the pathogenesis of
the disease. Microglia are the resident immune cells (macrophages) of the brain and
constitute the first line of active immunological defense in the CNS. Usually present in
the resting state, they are activated upon an immune challenge or insult in the brain, such
as disease or injury. They are recruited to the site of damage, where they phagocytose
debris as well as dying or unwanted cells57. Apart from mediating immune responses to
infection and trauma, microglia have been shown to play important roles in the patterning
and wiring of the developing, healthy, CNS57.
They participate in programmed cell death or apoptosis during neural development, by
phagocytosing excess neurons as well as mediating the process of apoptosis using
molecular cues57. Using their processes, microglia have been shown to survey the
functional state of the synapses57 and they also participate actively in the formation of
eye-specific territories by engulfing retinal ganglion cell synaptic inputs to dorsal lateral
geniculate nucleus (visual thalamus)
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. Microglia are also key players in synapse

function and maturation. It has been shown that knockout of the fractalkine receptor
present on microglia, CX3CR1, led to the reduction in functional connectivity between
two different regions of the brain59. Abnormal synaptic pruning due to the disruption of
neuron-microglial signaling, is thought to be the reason for this reduction in
connectivity59.
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Activation of microglia is marked by morphological changes accompanied with release
of various immunomodulatory signals. Cytokines and chemokines constitute a major
component of these signals where they participate in regulating the immune response,
and very importantly dictate the movement of leukocytes to the CNS, thereby
contributing to neuroinflammation.
Evidence of involvement of cytokines in ASD, came from a study, which compared the
levels of the cytokine tumor necrosis factor-alpha (TNF-α) in the serum and
cerebrospinal fluid of children with autism5. The pro-inflammatory cytokine TNF-α is
released predominantly by the glia in the brain and has many physiological roles in
normal brain functioning. An approximate 8-fold increase in the levels of TNF-α in the
cerebrospinal fluid as compared to the serum was reported5. This suggested an isolated
CNS immunological response in autism, independent of any systemic alterations.
However, systemic alterations have also been observed. Elevation in the levels of
chemokines like MCP-1, RANTES, eotaxin and non-chemokine cytokines like IL-6 have
been observed in the plasma of children with ASD as compared to normally developing
children6,7. Also, the elevations matched with the severity of the core behavioral
symptoms of autism6,7. Although the mechanisms linking immune dysregulation and
neural dysfunction had not completely been elucidated, these studies pointed towards a
role of cytokines and chemokines in impaired neurodevelopment.
1.3 Rodent models of maternal immune activation
The finding that maternal infection is a risk factor for autism necessitated suitable rodent
models to study the mechanism of development of the disease. Infection in the mother
was introduced through different mechanisms. Initial studies did respiratory infection of
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pregnant mice with human influenza virus8. The offspring showed hyperanxiety in novel
or stressful situations, which is common in autism patients8. In trying to investigate
whether the behavioral alterations observed were due to the viral infection of the fetus or
the maternal immune response, the investigators found that the effects of the viral
injection could be achieved by intraperitonial injection of the synthetic double-stranded
RNA poly (I:C) (PIC) to the mother during pregnancy. This showed that the maternal
immune response, even in the absence of the virus, was sufficient to cause the behavioral
changes observed in the offspring8. The placental transfer of maternal antibodies against
the viral mimic, PIC, possibly contributed to the behavioral deficits in the offspring. The
pathogenicity of placentally transferred maternal antibodies was demonstrated in a later
study, in which human IgG from mothers of children with autistic disorder (MCAD) were
administered to pregnant mice. The offspring of these mothers showed altered behavior
observed in autism such as hyperactivity and less sociability9. Behavioral patterns
observed in the offspring of immune activated mothers were also critically dependent on
the gestational age at which the infection was administered10.
Later, a well characterized model of maternal immune activation was established, which
displayed the three core symptoms of autism- deficits in social interaction, language and
the presence of repetitive/stereotyped behaviors in the offspring of mothers injected with
PIC.12
A mechanism by which maternal immune activation causes alteration of fetal brain
development was demonstrated in a study showing that elevation of the pro-inflammatory
cytokine IL-6, was responsible for the behavioral deficits observed upon maternal
immune activation11. A single maternal injection of IL-6 on embryonic day 12.5 of
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mouse pregnancy was shown to cause prepulse inhibition (PPI) and latent inhibition (LI)
deficits in the adult offspring, behaviors which model deficits in sensorimotor gating11.
Upon co-administering an anti-IL-6 antibody in the PIC model of MIA the deficits
caused by PIC were prevented11. Also, MIA in IL-6 knock-out mice did not result in
several of the behavioral changes observed upon activating the maternal immune
system11. These findings gave rise to the thought that the balance between pro- and antiinflammatory influences was critical in fetal brain development. Further investigation
into the mechanism by which IL-6 influenced fetal brain development showed that
maternal immune activation led to an increase in both maternally derived IL-6 mRNA
and protein in the placenta14. The placenta also showed an increase in various immune
cells such as macrophages, granulocytes and uterine NK cells, which were indicative of
early immune activation14.
A proposed model tries to explain the effects mediated by IL-6 in MIA on the placenta
and thereby fetal development14. Upon injection of PIC to mother, the maternal immune
system is activated via a TLR3- mediated anti-viral response14. Activated TLR3+ cells
secrete pro-inflammatory factors, such as IL-6, into the maternal bloodstream14.
Circulation of maternal blood containing IL-6 through the placenta leads to increase in
IL-6 in the decidua and spongiotrophoblast, which leads to activation of the resident
immune cells in the decidua, and they propagate the inflammatory response by further
cytokine release14. IL-6 release from decidual cells acts on target cells in the
spongiotrophoblast layer by paracrine signaling14. IL-6 ligand upon binding to receptor
IL6Ra and gp130 leads to JAK/STAT3 activation and downstream changes in gene
expression leading to reduced GH (growth hormone), IGF-1 (insulin-like growth factor-
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1) and IGFBP3 leading to disruption of the GH-IGF axis14. Also, there is alteration in
production of placenta-specific prolactin like proteins (PLPs)14. These changes in
endocrine factors in the placenta has effects on fetal development14.
The MIA model was utilized to study long-term changes in the brains of the offspring of
MIA mice. Multiplex array analysis studies showed that MIA leads to age and regionspecific changes in the levels of different cytokines in the brain and sera of the
offspring13. These cytokines are both pro- and anti-inflammatory. This study provided
further support to the importance of these molecules in the mechanism of disease
development in ASD. Other abnormalities observed in the brains of MIA offspring
include altered cerebellar pathology, similar to what is observed in the brains of autism
patients15. In conclusion, these studies demonstrated how immune activation of the
mother can have global and long-lasting effects on brains of the offspring.
1.4 Effect of maternal immune activation on the synapse
Maternal infection can affect any step in neural development, and synaptogenesis is one
of the most critical steps in neural development. Current research in the field of
understanding the mechanisms of development of ASD has a strong focus on the role of
the synapse60.
A study of dendritic spines, the post-synaptic compartment of excitatory synapses, on
cortical pyramidal cells revealed an increase in dendritic spine densities in ASD patients
as compared to age-matched controls19. In fact, some of the genetic mutations which
confer a risk for autism, are present in synaptic genes. e.g, point mutations in Shank3,
which is a post-synaptic scaffolding protein, have been identified in ASD patients17,18.
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Other examples of synaptic genes mutated in ASD patients are Tsc2, Fmr1, Neuroligin-3,
Neurexin-1 etc. The interrelatedness of the functions of these proteins mean that the
defect in any one of these proteins is capable of triggering a cascade of reactions
affecting other synaptic proteins and therefore leading to synaptic network deficits.
The only study to have directly looked at the effect of MIA on synapses, showed a
reduction in synaptic density in cultured cortical neurons from MIA neonatal offspring25.
In other studies which examined the effect of MIA on synaptic function, induction of
inflammation, prenatally, using lipopolysaccharide (LPS), was shown to give rise to
altered glutamatergic transmission in the adult offspring20. This effect was shown to be
mediated by activated microglia at birth, due to prenatal inflammation20. Also,
examination of synaptic properties in hippocampal CA1 pyramidal neurons of the
offspring of PIC-treated mothers showed reduced frequency and increased amplitude of
miniature excitatory postsynaptic currents21. Very recently, it has also been shown that
the adult offsprings of MIA mothers have shown deficits in hippocampal long term
potentiation27, a cellular mechanism of synaptic strengthening. All these examples give
evidence of the fact that maternal immune activation is indeed capable of affecting
synaptic structure and function. Also, these findings lend credence to the school of
thought that synaptic deficits may be the starting point of neural dysfunction in ASD.
1.5 Molecular mechanisms of synaptic deficits in MIA model
The elucidation of the link between prenatal inflammation and synaptic impairments
leading to cognitive dysfunction is critical for understanding the mechanisms of
development of ASD and also for identification of therapeutic targets. Immune
molecules, which have been shown to be dysregulated in the MIA offspring, are now
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known to play essential roles in the healthy brain such as establishment, function and
alterations of synaptic networks. These include cytokines like IL-6 and TNF-α,
complement proteins such as C1q and C3 and MHCI (Major Histocompatibility Complex
I) family members.
It is now known that MHCI expression in the normal, developing brain plays a critical
role in regulating synaptogenesis. In early post-natal brain development, MHCI was
shown to negatively regulate the density and function of cortical synapses, during their
initial establishment24. Also, expression of MHCI was needed for refinement of synaptic
inputs to Lateral geniculate nucleus (LGN) neurons, so that eye-specific separation of
connections is achieved22,23. These findings showed the role of MHCI in regulating
structural and functional synaptic plasticity. Hence, it can be expected that disruption or
alteration of MHCI expression can lead to synaptic deficits thereby leading to cognitive
dysfunction such as ASD. Evidence of immunological dysfunction in ASD lends support
to this argument. Investigation into how MHCI exerts its effect on synapses, has shown
that MHCI, in an activity-dependent manner, activates a pathway that also contains the
transcription factor, MEF2, and this pathway plays a role in negatively regulating synapse
density25. In fact, cultured cortical neurons from MIA neonatal offspring show a
reduction in synaptic density, and an increase in the levels of MHCI and MEF225. This
deficit in MIA offspring requires increased MHCI-MEF2 signaling25. This study
elucidated the mechanism by which MHCI plays an important role in the early post-natal
brain development of MIA offspring.
The initiator of the complement cascade pathway, C1q, has been shown to be expressed
in developing brains and participate in synaptic elimination, thereby fine-tuning the
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synaptic connections26. This finding is further supported by the observation of enhanced
synaptic connectivity and epilepsy in C1q knockout mice27. However, the role of C1q
mediated synaptic pruning in MIA has not yet been explored, but it is possible that it may
also have a role.
Further investigations into the molecular mechanisms of synaptic deficits, which utilize
the MIA model can shed light upon how critical synaptic deficits are in the development
of the disease, and can also provide targets for reversal for these deficits, to test whether
reversal of synaptic deficits can take away any of the symptoms associated with ASD.
1.6 Role of astrocyte in synaptic development and function
In the CNS, the synapses are ensheathed by astrocytes, which are glial cells. The intimate
association, both structural and functional, of the perisynaptic astrocytes with the
synapse, has led to the concept of the ‘tripartite synapse’32. In this, synapses are defined
as being composed of the presynaptic and postsynaptic specializations of the neurons,
and the astrocytic processes ensheathing them32. Functionally, besides supporting
neuronal function by regulating blood flow, providing energy to neurons and supplying
the building blocks of neurotransmitters, astrocytes also express receptors for
neurotransmitters, which allow them to sense neuronal activity and respond to it33.
Astrocytes respond to neuronal activity by making changes in intracellular calcium ion
concentrations33. Fluctuations in intracellular calcium ion concentrations are a
manifestation of astrocyte excitability, although they are electrically non-excitable, unlike
neurons. Besides neuron-dependent excitation, astrocytes can also exhibit spontaneous
Ca2+ oscillations, which are independent of any neuronal input36. Closely linked with
these fluctuations in calcium levels are the release of various neurologically active
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substances or gliotransmitters, such as ATP and D-serine33. By the release of these
factors, the astrocytes are capable of modulating synapses such as controlling synapse
formation, elimination and synaptic connectivity33. There are other mechanisms by which
astrocytes are capable of modulating synapses, which are dependent on Ca2+ elevations in
astrocytes. It has been shown that stimuli which induce synaptic LTP in the
hippocampus, also enhance the motility of astrocytic processes associated with these
synapses61. This motility is dependent on Ca2+ elevations in astrocytes and also leads to
changes in the ability of astrocytes to regulate synaptic transmission61. These were shown
in hippocampal slice preparations. Similar observations were also made in vivo, where
sensory stimuli which led to increases in astrocyte Ca2+, induced structural plasticity in
astrocytic processes and dendritic spines in the mouse somatosensory cortex 61. The
structural plasticity of astrocytic processes in response to Ca2+ elevations was also
correlated with spine coverage and stability62.
Cytokines have been shown to have an effect on gliotransmission. Glutamate release
from astrocytes has been shown to be controlled by inflammatory molecules such as
TNF-α and prostaglandins, by a calcium dependent mechanism38,39. These results suggest
that production of these mediators in pathological conditions, may affect gliotransmission
and astrocyte excitability.
The metabolic coupling between neurons and astrocytes has been shown to be affected in
ASD. Astrocytes communicate within multicellular syncytium of astrocytes and neurons
using connexin-based gap junctions (specifically Cx43)40 . It has been shown that in ASD
patients, there is an elevation of Cx43 expression in astrocytes, which will affect the
astrocytic syncytia41. Also, astrocytes are an important component for the glutamate-

11

glutamine shuttle, which is critical for excitatory glutamatergic signaling in neurons.
Glutamatergic signaling has been strongly involved in the pathology of ASD because
alterations in excitatory signaling are critical for cognitive functions such as memory and
learning, which are impaired in ASD patients40. Alterations in synaptic glutamate
concentrations have been shown in a model of autism42, and patients with ASD have been
shown to have abnormalities in the glutamate transporters in the cerebellum43.
However, the contribution of astrocytes in the MIA model remains unexplored. Here, I
have hypothesized that MIA results in altered astrocytic Ca2+ signaling resulting in
altered synaptic development.
1.7 Modeling behavioral deficits in ASD
ASD is diagnosed using behavioral symptoms, and there is a great degree of diversity of
symptoms in ASD patients. The diagnostic manual of the American Psychiatric
Association, DSM-V, outlines the criteria used for diagnosis of ASDs, which includes
persistent deficits in social communication and interaction, restricted and repetitive
patterns of behavior, interests and activities and requires that these symptoms be present
in the early developmental period, causing significant impairments in social, occupational
or other areas of functioning.
Behavioral deficits in rodent models are used as an important marker for the
manifestation of ASD. “ASD-like behavior” has been used extensively for the
characterization of rodent models in the case of many genetic models of ASD as well the
MIA environmental model of autism. However, it is indeed challenging to design mouse
or rat behavioral tasks that are relevant to the symptoms seen in human patients. Some of
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the most commonly used assays for ASD in rodent models such as mouse models observe
for abnormalities in social interactions, communication deficits and repetitive
behaviors31.
The parameters evaluated in mice to assay social interactions look at sniffing, following,
pushing and crawling over each other with physical contact, chasing, mounting and
wrestling31. One commonly used experiment measures the time spent with an inanimate
object versus a novel mouse. A normal mouse would spend more time in the chamber
containing the novel mouse as compared to mice having ASD related mutations31. Other
tests evaluate social memory, recognition and affiliation and also social transmission of
food preference31. Communication deficits are assayed by measuring the interest in
urinary scents from other mice, olfactory habituation to social odors, preference for social
odors over non-social odors, and measurement of ultrasonic vocalizations31. Repetitive
behavior is measured by scoring motor stereotypies, repetitive self-grooming, insistence
on sameness and restricted interests such as restricted exploratory behavior in a novel
environment31. A test for repetitive behavior, that has been used in the characterization of
deficits in the MIA offspring is marble burying, a repetitive digging behavior12. This test
presents a novel situation and is capable of evoking a highly repetitive and stereotyped
response, which is scored by counting the number of unburied marbles12. The MIA
offspring have been shown to bury 2.8 fold more marbles as compared to controls12.
Few studies have looked at the links between synaptic changes, circuit dysfunction and
behavioral abnormalities. However, mutation in NL3 gene, which is a post- synaptic cell
adhesion molecule, has been shown to cause acquisition of repetitive motor routines,
using the rotarod54. The rotarod test is typically used for evaluating motor skill learning,
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However, in this study, increased time spent on the rotarod was interpreted as being due
to repetitive movements of mice having mutations in the NL3 gene54. This increased
learning was attributed to a synaptic impairment in the nucleus accumbens54.
In this thesis, I have tried to explore whether any differences are observed in MIA mice
as compared to controls, by comparing the time spent running on the rotarod, due to
increase in repetitive movements. Any differences observed would point towards possible
synaptic alterations in the MIA mice.
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Chapter 2- EXPERIMENTAL PROCEDURES-

2.1 Induction of MIAMIA is induced in the mother by intraperitonial injection of synthetic dsRNA, Poly I:C
potassium salt (Sigma Aldrich; St. Louis. MO) at a dose of 20 mg/kg at embryonic day
12.5 (E12.5)12. The control mother is injected with Saline at the same time E12.5
2.2 Marble buryingMice are tested at P60 (Postnatal day 60). There are two cages that are needed to test one
litter of animals- the acclimatization cage and the testing cage. Both the cages have the
same bedding set up. Corn cob bedding upto a depth of 3.5 cm and Tek-fresh bedding
with total weight of 200g are thoroughly mixed and distributed evenly throughout the
cage. 24 hours prior to testing, the mice are placed in the new cage and allowed to
acclimatize overnight.
On the day of the testing, the weights and sex of the animals are recorded. Testing is done
from 12pm to 5pm. Prior to testing, the animals are acclimatized for 30 minutes in the
testing cage, which does not have any food and water. For testing, 30 marbles are added
to the same cage in a 5X6 arrangement. One mouse at a time is placed in the cage with
marbles, and allowed to be in the cage for 30 minutes. Periodically, the mouse is checked
for signs of activity, to ensure that the mouse is not sleeping. After 30 minutes, the mouse
is removed in such a way, so as to not disturb the arrangement of marbles in the cage.
The number of marbles which are greater than 2/3rd buried in the bedding are counted and
recorded as the number of buried marbles. The percentage of marbles buried is recorded.
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2.3 Rotarod6-week old mice are used for this task. Rotamex4/8 4-lane machine (Columbus
Instruments) is used for testing.
HabituationPrior to testing, the mice are habituated on the rotarod at a constant speed of 4 rpm for 3
minutes for Day 1 and 2 and at constant speed of 8 rpm for 3 minutes for Day 3. If the
mice fall off during the course of the 3 minutes, they are again put back on the rod till
they complete a total period of 3 minutes on the rod. They are then given a break of 10
minutes.
TestingTesting consists of 3 trials in a day separated by an interval of 10 minutes each, for 3
days. The paradigm- 4-40 rpm for 5 minutes for Day 1 and Day 2, 8-79 rpm for 5 minutes
for Day 3
The mice are placed on the rotating rod and allowed to run on the rod. When the mice are
unable to keep up with the speed, they fall down. The rod stops rotating when the mice
fall, and the total duration for which they stay on the rod is displayed. This is noted as the
latency. The latency (in seconds) is plotted against trial number, for a total of 12 trials.
2.4 Breeding strategy for GCAMP3 transgenic miceTransgenic mice expressing the genetically encoded calcium indicator, GCAMP3 in
astrocytes, are used. Two mouse lines are crossed: one that expresses the CreER
recombinase under the control of an astrocyte specific promoter GLAST, and the other
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line carrying loxP sites flanking a STOP codon upstream of the gene of interest,
GCAMP3 (GCAMP3f/f mice).
2.5 GCAMP3 expression4-Hydroxytamoxifen (Sigma-Aldrich Inc., St Louis, MO) is injected intraperitonially into
the pups that are Cre+ flox+ ,for the expression of GCAMP3 in the astrocytes. The
injections are on P5 and P7. Each pup receives a total dose of 0.5 mg per injection.
2.6 CraniotomyAnimals between the ages of P18-P21 are used. To perform imaging in the brain, a
craniotomy is performed in the somatosensory cortex by removing a 1-2 mm wide
portion of the skull in both the hemispheres. The surgery is performed under 1-1.5%
isoflurane. After the cortex is exposed, SR101 dye (Sigma- Aldrich Inc., St Louis, MO)
at a final concentration of 100 μm (prepared by adding 1μl of 5mM stock of SR-101 to 50
μl of ACSF solution) is loaded on the cortex for 20 minutes, and washed out for half an
hour. This is done to label the astrocytes, so that they can be used as a structural marker
to locate the astrocytes and check for GCAMP3 expression.
2.7 In vivo multiphoton imagingImaging is performed with a multiphoton microscope (Moving Objective Microscope
(MOM), Sutter), using a Ti:sapphire laser (Chameleon Vision II, Coherent) tuned to 920
nm. Images are collected with a Nikon water immersion objective (60X, 1.0 NA). For
imaging, ScanImage software (Pologruto et al., 2003) written in MATLAB (MathWorks)
is used. All imaged astrocytes are in layer 1 (within the first 100 μm below the dura
mater) within the somatosensory cortex. Time lapse imaging is done at a single focal
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plane for 5 minutes and images are acquired every 2s. A total of 150 images are collected
in a span of 5 minutes. Image acquisition is done at zoom 3 on two different channels- the
red channel (610/75) for the SR101 labeled astrocytes and the green channel (535/50) for
the GCAMP3 labeled astrocytes. Each image is collected at 256 X 256 pixels, 0.36
μm/pixel.
2.8 Image analysisImages are analysed using ImageJ software. Images are first corrected for Z- drift and XY drift. The SR101 labeled cells are Z-projected and regions of interest are put around the
soma and processes of the cell. The fluorescence intensity is calculated for each region of
interest and the background is subtracted. Baseline fluorescence values are calculated and
ΔF/F percentage values are calculated where ΔF is the difference from the baseline
fluorescence values.35 The transients that have fluorescence values higher than three
standard deviations are counted as transients showing calcium activity. Average of the
number of calcium transients will be taken for each Region of Interest (ROI) to give the
number of transients per cell.
2.9 Calculation of frequency, amplitude and duration of calcium transientsThe average of number of transients per cell is averaged for all the cells analysed per
animal to give the frequency of calcium transients per animal. The amplitude of the
transients are calculated and the duration is calculated at 50% of the amplitude. These
values are then averaged per cell, to give one value per animal.
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Chapter 3- RESULTS AND DISCUSSION

3.1 Experiment 1- To test whether treatment with anti-inflammatory drug Ibudilast
(AV-411) ameliorates marble burying deficits in MIA mice
Marble burying is used as a test for evaluating repetitive and stereotypic behavior in
small rodents

46

. Previously, it has been demonstrated that C57BL6 MIA offspring

display increased marble burying as compared to control mice12. Since, it has been shown
that most of the behavioral deficits observed in MIA are mediated by increase in the
levels of inflammatory cytokines like IL-611, we wanted to test whether treatment with an
anti-inflammatory drug can reverse the increase observed in marble burying. Ibudilast
(AV-411) is an anti-inflammatory drug, which is a type- 4 phosphodiesterase inhibitor
and can cross the blood-brain barrier. It has been shown to suppress the production of
Nitric Oxide (NO), Reactive Oxygen Species and pro-inflammatory cytokines such as IL1β, IL-6 and TNFα from activated microglia as well as enhance the production of antiinflammatory cytokines such as IL-10 and other neurotrophic factors such as NGF,
GDNF and NT-4 in activated microglia, in a dose-dependent manner 47,48. By doing so, it
exerts a neuroprotective effect and promotes neuronal survival in the presence of
activated microglia.
Since published work25 and data from our lab indicate that MIA results in altered synaptic
formation in the first few postnatal weeks, we wanted to reverse any potential
inflammatory-induced synaptic changes early in development. To avoid handling and
potentially stressing the young MIA pups, the lactating mothers were injected with 30
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mg/kg Ibudilast or vehicle daily for two weeks starting one day after parturition. The
MIA and control offspring were tested for marble burying on P60 (Post natal day 60).
After the initial pilot study showing that MIA increases marble burying and that Ibudilast
reduces it, I investigated if Ibudilast also affects marble burying in control mice. To keep
me blinded additional litters from other groups were also included.

It was observed that MIA offspring treated with vehicle buried 44% more marbles as
compared to control mice treated with vehicle (Con+Veh: 37±3.2%, n=20 mice;
MIA+Veh: 53±2.8%, n=17 mice, Two- way ANOVA, post-hoc Tukey’s test, P=0.002).
Also, treatment of MIA offspring with Ibudilast during the first 2 postnatal weeks
normalized the marble burying behavior (MIA+Ibud: 36±3.2%, n=14, P=0.003). In the
control, drug treated mice there was a trend but not a significant reduction in marble
burying (Con+Ibud: 28.66±3.59%, n=14, P=0.06).
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The anti-inflammatory drug, Ibudilast was able to rescue the behavioral deficits observed
in MIA offspring. These results are consistent with the interpretation that the
inflammatory state in the developing brains of MIA mice is responsible for the observed
behavioral deficit in marble burying.
3.1 a) DiscussionThe drug, Ibudilast, mediates its neuroprotective effects by inhibiting the production of
pro-inflammatory cytokines such as IL-6 and upregulating the production of antiinflammatory cytokines such as IL-10 and neurotrophic factors from activated
microglia47,48. Prenatal intraperitonial injection of IL-6 to the mother has been shown to
cause ASD- relevant behavioral deficits in the offspring11,13. Drawing from these
observations, it can be hypothesized that the reversal in the marble burying behavior upon
administration of Ibudilast, could be due to the restoration in the balance of pro and antiinflammatory cytokines in the brains of MIA offspring. However, it has been reported
that there is no increase in the density of microglia or any qualitative changes in
microglial morphology, which might be indicative of microglial activation, in the brains
of MIA offspring13. Therefore, the exact mechanism by which Ibudilast causes reversal of
behavioral deficits in MIA offspring, is still unclear. This also brings ambiguity about
whether the effects of the drug are being mediated by acting upon the brain or it has other
systemic effects. To check whether pro-inflammatory cytokines like IL-6 are reduced
upon administration of Ibudilast, brain lysates from mice before and after administration
of the drug can be collected, and checked for levels of different pro-inflammatory
cytokines using ELISA. This will also give a better idea about whether the effects of the
drug are being mediated by acting upon the brain or is it due to other systemic effects that
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the drug has. It has been shown that some behavioral abnormalities of MIA mice can be
corrected by irradiating them and transplanting them with bone marrow from wild-type
mice53. Also, examination of cytokine production from bone-marrow derived
macrophages in adult MIA offspring revealed increased production of the proinflammatory cytokine IL-12 and the chemokine, CCL363. This suggested the increase of
M1 polarization in macrophages, which results in increased production of the natural
killer cell and TH1 cell activating cytokine IL-12 and very low levels of antiinflammatory cytokine IL-1063. These observations imply that the reversal in increased
marble burying could be due to other mediators, outside the brain too.
This is the reason why it is important to determine how much of the drug, which is being
administered intraperitonially, is reaching the brain. A full pharmacokinetic study of
Ibudilast has not been performed yet, but preliminary LC-MS measurements 4 hours after
injection of the drug to the mother has revealed presence of the drug in serum and brain
of the pups.
Here, it is also important to take into account the neural circuits that are implicated in
repetitive behavior. Historically, basal ganglia has been the most prominent candidate for
explaining repetitive behavior, very specifically, motor stereotypies49.
Refinement of earlier understanding has identified three “macro-circuits” which are
defined by the cortical output to the striatum. These are the sensorimotor (movement),
associative (cognitive functions) and limbic (emotional-motivational behavioral)
circuits50. These cortical inputs are partially overlapping and a disruption of coordination
within the basal ganglia or between cortical and striatal structures may reflect in the
development of repetitive behavior51.
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It has been suggested that the motor loop is mainly involved in stereotypical motor
behavior, specifically while repeating identical movements without a goal, an example of
which is marble burying52.
However, it is unknown how dysregulation of inflammatory molecules affects these
circuits. Unpublished data from the lab has shown that there are structural and functional
synaptic deficits in the form of reduction in the density of dendritic spines in the cortex of
MIA offspring, accompanied by alterations in excitatory and inhibitory synaptic
transmission. Some synaptic impairments are prevented upon treatment with Ibudilast.
Hence, it is clear that synaptic networks are affected in the brains of MIA mice, which is
probably reflected in the altered behavior. The correlation between the synaptic and
behavioral deficits becomes clear from the fact that both the deficits are reversed by
treatment with Ibudilast. However, the exact molecular mechanism, which is the “trigger”
for these changes, remains unknown. It can be speculated that the disbalance in the
cytokine levels in the brain could be a possible trigger for these changes, setting into
motion a cascade of events, which eventually culminates into synaptic and behavioral
deficits observed in MIA offspring.
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3.2 Experiment 2- To establish a new behavioral paradigm for MIA offspring using
the rotarod.
To better model human ASD behaviors in mice it is desirable to test different paradigms.
Having established that MIA offspring have an impairment in a behavior that models
repetitive behavior in ASD, we set out to determine if a different recently developed
paradigm54 for repetitive behaviors will detect impairments in MIA mice. This behavior
also identified the specific synaptic circuit (including the neurons that the synapse project
onto)54 that was impaired in this behavior, which would give us some insights into the
synaptic circuits that might be impaired in MIA, if any deficits were observed.
Motor coordination and learning in the offspring of mothers who were administered a
respiratory system infection using influenza virus 8 and from mothers injected with PIC 27
had been tested using a paradigm in which the rod accelerates from 4-40 rpm in a span of
5 minutes. Such a paradigm, tests gross motor function over a period of days and is
measured by increased time spent by the mice running on the rod, before they are unable
to keep up with the accelerating speed and fall down 8,27.
A new test of motor coordination, was able to show significant differences between
control animals and animals which had mutations in the autism-associated gene NL354.
This test was for 4 days and consisted of two parts-the first part was for the first two
days, and the acceleration of the rod was from 4-40rpm within 5 minutes. The second
part was for Day 3 and 4 where the rod accelerated from 8-80 rpm within 5 minutes. The
differences observed were more pronounced in the second part of the test. The increased
time spent running on the rod was attributed predominantly to enhanced acquisition of
repetitive motor routines due to mutations in NL3 gene.
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Since repetitive behavior has also been shown in the MIA model, I wanted to establish if
in this paradigm we can also detect increased repetitive behavior in the MIA offspring. In
the paradigm I used, on the first two days the mice were allowed to run on the rod while
it accelerated from 4-40 rpm in 5 minutes. On the last day, the mice were tested on the
rod, while it accelerated from 8-79 rpm within 5 minutes.
Each day consisted of 3 trials separated by a time interval of 10 minutes each. The time
spent by each animal running on the rod was plotted against the trial number.

The saline group consisted of 6 animals (n=6) from 1 litter and the MIA group consisted
of 10 animals (n=10) from 3 litters. In the first part of the test (4-40 rpm, Day 1 and 2),
there is increase in latency over trials in both the groups, although insignificant (Repeated
measures ANOVA, P=0.2436). However, there is no difference between the two groups
(P=0.4530). In the second part of the test (8-79 rpm, Day 3), there is no difference in
latency over trials in both the groups (P=0.4110), however, there is a trend towards
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higher latencies in the MIA group (P=0.0790), suggesting a better repetitive motor
routine in MIA offspring.
3.2 a) Discussion
Our results have demonstrated that MIA offspring do not have impairment in basic motor
coordination as is tested by the 4-40 rpm paradigm. This result is consistent with earlier
reports where no differences in motor function were observed in the offspring of mothers
who were administered a respiratory system infection using influenza virus 8 and from
mothers injected with PIC 27, and tested using the rotarod.
The rotarod is traditionally used as a test for motor learning and coordination. However,
in a recent study of NL3 mutation54, it was used as a proxy for testing enhanced repetitive
behavior. The act of running on the rod for a longer period of time was interpreted as
being due to enhancement in the learning of repetitive motor routines54. Such a behavior
can be classified as goal-directed repetitive behavior, which is thought to be controlled by
the loop receiving inputs from the prefrontal cortex into the striatum.55
It was shown that mutations in NL3 impaired specific synaptic inputs in the nucleus
accumbens54, which is a part of the ventral striatum, causing enhancement in learning of
repetitive motor routines.
Although other forms of motor stereotypies have been demonstrated in the MIA model
such as the marble burying, this test is unique in the way it ties repetitive behavior to
motor coordination. The fact that the MIA mice have a trend towards achieving higher
latencies as compared to Saline mice, despite not learning, could be due to enhanced
motor coordination, which is attributed to presence of repetitive behavior. This points
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towards involvement of multiple overlapping brain circuits in ASD, beyond cerebellum
and dorsal striatum. Also, it gives a starting point to look for specific synaptic
impairments linked to behavior in the MIA model. Unlike the previously characterized
repetitive behavior test, marble burying, this test involves the whole body. The unique 879 rpm paradigm brings out the differences between the two groups, by creating more
difficult conditions for the mice to keep up with and pushing them harder. Although, the
difference between the two groups is not significant, there is a trend, and it would be
interesting to see whether it persists and becomes significant upon addition of more
animals.

27

3.3 Experiment 3- To compare basal levels of astrocytic calcium activity in control
and MIA offspring.
Cytokines have been shown to have an effect on gliotransmission. Glutamate release
from astrocytes has been shown to be controlled by inflammatory molecules such as
TNF-α and prostaglandins, by a calcium dependent mechanism38,39. These results suggest
that dysregulation in the production of these mediators in conditions such as those which
are thought to exist in the brains of MIA mice13, may affect gliotransmission and
astrocyte excitability. Astrocyte excitability can be assayed by measuring intracellular
calcium (Ca2+) signals36. Thus, it was hypothesized that the astrocytic Ca2+ activity is
altered in the brains of the MIA offspring. Astrocytic Ca2+ elevations have been also
shown to modulate synaptic structure, function and stability61,62. Hence, we wanted to
image astrocytic calcium during spine formation and stabilization in MIA offspring.
Astrocytic Ca2+ signals are representative of excitability due to both neuronal inputs as
well as spontaneous changes in intracellular Ca2+ levels36. Most importantly, the Ca2+
dynamics represent encoded signals in both neuron-to-astrocyte as well as astrocyte-toneuron signaling56. In the absence of any external neuronal stimulation such as sensory
stimulation, the astrocytic Ca2+ levels represent the basal level of astrocytic Ca2+ levels.
Genetically encoded calcium indicators (GECIs) are an effective tool to image
intracellular [Ca2+] in astrocytes56. These can be expressed in genetically-defined cell
populations and allow the monitoring of Ca2+ activity in the fine astrocytic processes
such as branches and endfeet, besides the soma, which makes it a more desirable
technique than bulk-loading and patch dialysis of Ca2+ indicator dyes56. Other relevant
characteristics are signal-to-noise ratio (SNR), Ca2+ affinity, rise and decay kinetics,

28

dynamic range, photostability, compatibility with long-term imaging, and targeting to
specified locations and fusion proteins56.
GCaMP is a genetically encoded calcium indicator, created from a fusion of GFP,
Calmodulin and M13, a peptide sequence from myosin light chain kinase. Upon Ca2+
binding to Calmodulin, there is a conformational change in the fluorescent protein,
resulting in bright fluorescence56.
For our experiments, we used GCAMP3 transgenic mice that were crossed to GLASTCre-ER. The pregnant female was injected with PIC at E12.5, to induce MIA. The
offspring that expressed both CreER and loxP were injected with 4-Hydroxytamoxifen
twice between the ages of P5 and P10. This leads to translocation of CreER into the
astrocytic nuclei, excision of the STOP codon, and expression of GCAMP3 in the
astrocytes. Surgery and imaging was done between P18 to P25 because previous studies
in the lab have detected significant synaptic impairments at P17.

Craniotomy was performed on the mice, which had been injected with 4-HT, and topical
application of SR-101, a morphological marker of astrocytes was performed.
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The mice were allowed to wake up after the surgery and multiphoton microscope was
used to image different fields of view containing astrocytes labeled with GCAMP3 and
the morphological marker SR-101, in awake mice. Images were acquired over a time
frame of 5 minutes, every two seconds.
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In Figure 5b) At the beginning of the acquisition period, all the three GCAMP3 labeled
astrocytes appear silent. In the middle, the cell 1 lights up, showing the occurrence of a
somal transient. At the end of the acquisition period, there is activity in the processes of
the other two cell 2 and cell 3.
For quantification of these transients, ImageJ is used. Regions of interest are marked on
the cell body and processes, using SR-101 labeling as a marker. Fluoresence intensity in
each of the marked ROIs is measured, background subtracted, and the difference from the
basal fluorescence intensity is calculated as a percentage. Qualification as a transient
requires that it should be greater than two standard deviations. Amplitude of a transient is
calculated and the duration is calculated at 50% of the amplitude.

The figure shows two traces from a process and a soma respectively. The somal trace and
the process trace show one transient each.
A total of 16 cells (astrocytes) from 16 different fields of view were analysed. These 16
different fields of view were from 5 different animals, 3 Saline and 2 MIA. However, no
result could be obtained from these experiments because there was very little activity
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observed in my experiments despite the fact that these animals were imaged under awake
conditions. This indicated that the experiments were not working in the correct manner.
3.3 a) Discussion
We had hypothesized that the astrocytic calcium activity is altered in the brains of MIA
offspring. Although GCAMP3 expressing mice had been successfully used to image
astrocytes in vivo in older mice at age P30-P60, I was unable to test this hypothesis in the
young GCAMP3 mice, due to inability to reliably measure astrocytic calcium activity.
Also, the GCAMP3 labeling in astrocytes was sparse in most of my experiments.
It was concluded that the best GCAMP3 expression was attained when imaging was done
around 3 weeks after the first 4-HT injection. Hence, the best time to inject animals
would be P5 and P7. This would allow sufficient time for effective recombination and
good expression of GCAMP3 in astrocytes, which is critical for performing these
experiments and to be able to differentiate between a signal and noise during analysis.
The second critical factor governing GCAMP3 expression is a good cranial window for
imaging. A good quality cranial window will have absence of any bleeding during or
after surgery. SR-101 labeling is a good marker for the quality of a cranial window. Clear
and crisp SR-101 labeling indicates absence of any bleeding in the window, and also
indicates that most of the cells have taken up the dye. Poor quality of the window may
result in absence of any activity in the GCAMP3 channel. Also, poor SR-101 labeling
limits the number of ROIs that can be marked, therefore resulting in loss of information.
Such windows should not be imaged, and if imaged, should not be considered for
analysis.
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If anesthesia during surgery, has affected the health of the animal, it will get reflected in
labored breathing, failure to revert back to a completely awake state, and often death of
the animal. The images acquired from such an animal are not considered valid and so the
health of the animal should be monitored closely throughout surgery and imaging.
It was decided that the induction would be done using 3% isoflurane and maintenance at
1.5-2% isoflurane, with 0.5 L/min oxygen throughout induction and maintenance.
Therefore it was concluded that the primary factor governing valid acquisition of images
is the presence of calcium activity. Activity can only be observed if there is GCAMP3
expression, which is in turn governed by the ages at which 4-Hydroxytamoxifen was
administered, age at which surgery and imaging was performed, quality of cranial
window, and imaging conditions.
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